CA3024113A1 - Heterocyclic compounds as kinase inhibitors - Google Patents

Heterocyclic compounds as kinase inhibitors Download PDF

Info

Publication number
CA3024113A1
CA3024113A1 CA3024113A CA3024113A CA3024113A1 CA 3024113 A1 CA3024113 A1 CA 3024113A1 CA 3024113 A CA3024113 A CA 3024113A CA 3024113 A CA3024113 A CA 3024113A CA 3024113 A1 CA3024113 A1 CA 3024113A1
Authority
CA
Canada
Prior art keywords
alkyl
cycloalkyl
cancer
arb
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3024113A
Other languages
English (en)
French (fr)
Inventor
Tong Wang
Stephen Gately
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Translational Drug Development LLC
Original Assignee
Translational Drug Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Drug Development LLC filed Critical Translational Drug Development LLC
Publication of CA3024113A1 publication Critical patent/CA3024113A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA3024113A 2015-05-18 2016-05-18 Heterocyclic compounds as kinase inhibitors Abandoned CA3024113A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562163369P 2015-05-18 2015-05-18
US62/163,369 2015-05-18
US201562203070P 2015-08-10 2015-08-10
US62/203,070 2015-08-10
PCT/US2016/033111 WO2016187324A1 (en) 2015-05-18 2016-05-18 Heterocyclic compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
CA3024113A1 true CA3024113A1 (en) 2016-11-24

Family

ID=57320732

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3024113A Abandoned CA3024113A1 (en) 2015-05-18 2016-05-18 Heterocyclic compounds as kinase inhibitors

Country Status (9)

Country Link
US (3) US10392402B2 (https=)
EP (1) EP3297437A4 (https=)
JP (1) JP2018515623A (https=)
CN (1) CN107835637A (https=)
AU (1) AU2016264220A1 (https=)
CA (1) CA3024113A1 (https=)
HK (1) HK1248070A1 (https=)
IL (1) IL255750A (https=)
WO (1) WO2016187324A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069016A1 (en) * 2008-11-13 2021-03-11 Gholam A. Peyman Neurodegenerative Disorder Treatment Method
CN105980365B (zh) 2014-02-11 2019-06-21 拜耳医药股份公司 作为mIDH1抑制剂的苯并咪唑-2-胺
AU2015217788B2 (en) 2014-02-11 2019-06-27 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Benzimidazol-2-amines as mIDH1 inhibitors
HK1248070A1 (zh) * 2015-05-18 2018-10-12 转化药物开发有限责任公司 作为激酶抑制剂的杂环化合物
AU2020273376C1 (en) * 2016-10-24 2024-02-29 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
US10807966B2 (en) 2016-11-21 2020-10-20 Translational Drug Development, Llc Heterocyclic compounds as kinase inhibitors
JP7490569B2 (ja) * 2018-04-24 2024-05-27 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としてのアミド化合物、組成物および処置方法
WO2020142745A1 (en) * 2019-01-04 2020-07-09 Translational Drug Development, Llc Methods of treating graft versus host disease and neoplastic disease with amide compounds
KR20220102622A (ko) * 2019-11-15 2022-07-20 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 Rock 억제제 및 이의 제조 방법과 용도
ES3015621T3 (en) 2019-12-31 2025-05-06 Ind Tech Res Inst Beta-amino acid derivative, kinase inhibitor and pharmaceutical composition containing the same, and use of the same
CR20220375A (es) * 2020-01-07 2022-09-22 Disarm Therapeutics Inc Inhibidores de sarm1
EP4192828A1 (en) * 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
CN116438171A (zh) 2020-09-16 2023-07-14 努拉生物公司 作为sarm1抑制剂的取代的吡啶衍生物
MX2024001322A (es) 2021-07-28 2024-04-30 Nura Bio Inc Derivados de piridina sustituida como inhibidores de sarm1.
KR20240176853A (ko) * 2023-06-15 2024-12-26 현대자동차주식회사 이중 전원 공급 장치, 그를 포함한 시스템 및 그 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8211919B2 (en) 2005-09-02 2012-07-03 Astellas Pharma Inc. Amide derivatives as rock inhibitors
CA2709883A1 (en) * 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
WO2009126635A1 (en) 2008-04-09 2009-10-15 Abbott Laboratories 2-amino-benzothiazole derivates useful as inhibitors of rock kinases
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
AR078793A1 (es) * 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
WO2011130740A2 (en) * 2010-04-16 2011-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
US8697911B2 (en) * 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012139930A1 (en) * 2011-04-11 2012-10-18 Nerviano Medical Sciences S.R.L. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
HK1248070A1 (zh) * 2015-05-18 2018-10-12 转化药物开发有限责任公司 作为激酶抑制剂的杂环化合物

Also Published As

Publication number Publication date
US20200255448A1 (en) 2020-08-13
AU2016264220A1 (en) 2018-01-04
CN107835637A (zh) 2018-03-23
IL255750A (en) 2018-01-31
US10392402B2 (en) 2019-08-27
US10633393B2 (en) 2020-04-28
HK1248070A1 (zh) 2018-10-12
EP3297437A1 (en) 2018-03-28
US20200017520A1 (en) 2020-01-16
JP2018515623A (ja) 2018-06-14
EP3297437A4 (en) 2019-02-27
US20180141959A1 (en) 2018-05-24
WO2016187324A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
US10633393B2 (en) Heterocyclic compounds as kinase inhibitors
US10807966B2 (en) Heterocyclic compounds as kinase inhibitors
AU2006299428B2 (en) Pyrimidine amide compounds as PGDS inhibitors
CA2441501C (en) Rho-kinase inhibitors
CN107406426B (zh) 作为rock抑制剂的环状脲类
CA3144548A1 (en) Heterocyclic compounds as inhibitors of kras g12c
WO2002076976A2 (en) Rho-kinase inhibitors
US20130150364A1 (en) Heterocyclic compound
BR112015012571B1 (pt) Compostos de imidazopiridina e usos terapêuticos dos mesmos
CA2844469C (en) N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
CA2688326C (en) Tetrahydroisoquinolin-1-one derivative or salt thereof
CA2863517A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
AU2009312032A1 (en) Carbamate compound or salt thereof
JP6756962B2 (ja) Ｐｉ３ｋ阻害剤とするピラゾロピリミジン化合物、該化合物を使用する医薬組成物と医薬、および該化合物を調製する方法
CA3168222A1 (en) Pyrrolopyrimidine derivatives and pharmaceutical composition for preventing or treating protein kinase-related disease comprising the same as an active ingredient
CA3120037A1 (en) Heteroaromatic compounds as vanin inhibitors
CN101933926A (zh) 作为pkc抑制剂的吲哚基马来酰亚胺衍生物
KR20060135035A (ko) 유사분열 키네신 억제제
CA3183661A1 (en) Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas
CN118084935A (zh) 咪唑烷酮类化合物及其制备方法与应用
CA3218159A1 (en) Rip1 modulators including azetidine cyclic ureas, preparations, and uses thereof
CA3193415A1 (en) Substituted 4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophene-2-carboxamide derivatives and use thereof
HK40013991A (en) Heterocyclic compounds as kinase inhibitors
HK1247927B (zh) 组合物、用途及其制备方法
HK1061030B (en) Rho-kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210510

FZDE Discontinued

Effective date: 20231120